SCHEMBL31246021

SCHEMBL31246021

CN(CCN1CCNCC1)C1CC(Oc2ccc(C(C)(C)O)cc2Br)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UTS2R Q9UKP6 14/20 0.35
▸ ALDH1A1 P00352 3/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ OPRD1 P41143 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ HTR1D P28221 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR1F P30939 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ CYP3A43 Q9HB55 1/20 0.32
▸ NPC1 O15118 1/20 0.31
▸ HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27391581 0.81 UTS2R (0.34) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL30824826 0.81 UTS2R (0.34) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL31246023 0.79 — —
SCHEMBL31245971 0.77 BRD4 (0.48) —
SCHEMBL30812132 0.73 IKBKB (0.39) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL31246014 0.72 BRD4 (0.42) HTR6
SCHEMBL30824772 0.72 UTS2R (0.34) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL27393380 0.72 UTS2R (0.34) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL31245970 0.70 PDE4D (0.42) ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL30812175 0.69 UTS2R (0.35) UTS2RHTR1ACYP2D6DRD2HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702022-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE Halda Therapeutics Opco, Inc. (US) 2026-03-04 — — EP disclosed
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2026-01-29 — — US disclosed
WO-2024211684-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS UTS2R 3046/4885ALDH1A1 211/4885ALOX15 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback